Taipei, Taiwan - September 4, 2024 - Tanvex BioPharma, Inc. (“Tanvex” or “the Company”, TWSE: 6541), the biosimilar-focused biopharmaceutical company and CDMO, today announced that its Board of Directors has appointed Stephen Lam as the Company's Chief Executive Officer, effective September 5, 2024. Stephen succeeds Henry Chen, who shall remain the Chairman until the closing of Tanvex’s...
Taipei, Taiwan, August 27, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today announced that its Board of Directors has approved a strategic investment into Tanvex Biopharma Co., Ltd. ("Tanvex", TWSE: 6541), whereby Bora Biologics, a wholly owned subsidiary of Bora and specialist large molecule CDMO, and Tanvex will combine their biomanufacturing facilities...
TAIPEI, TAIWAN, August 20th 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a a global leader in pharmaceutical manufacturing, today announced that it has completed the acquisition from Emergent BioSolutions (“Emergent”, NYSE: EBS) of its sterile manufacturing facility in Baltimore-Camden, Maryland. The facility adds drug product fill/finish to Bora’s extensive...
《HR Asia》, the leading HR magazine in Asia, recently announced the winners of the 2024 “The HR Asia Best Companies to Work for in Asia Awards.” Bora Pharmaceuticals stood out among nearly 370 participating companies, not only winning the prestigious HR Asia Best Companies to Work for in Asia Taiwan 2024 award for the second time but also receiving the HR Asia Most Caring Company Awards 2024, recognizing its commitment to the “People First” philosophy since its inception as one of the core competences of the Bora Group.